Table 2.
Non-FDA Approved Targeted Therapies Studied in Patients with Soft Tissue Sarcoma.
| Medication | Mechanism of Action | Target | Sarcoma Type |
|---|---|---|---|
| Regorafenib | Tyrosine Kinase Inhibitor | PDGFRα; VEGFR-1, -2, -3; c-kit | Non-adipocytic STS (61) Angiosarcoma (62) |
| Sorafenib | Tyrosine Kinase Inhibitor | Raf Kinase; VEGFR-2, -3; PDGFR-β | Desmoid Tumor (64) |
| Imatinib | Tyrosine Kinase Inhibitor | ABL; PDGFR; c-kit Possible CS1FR |
TGCT (65) |
| Sunitinib | Tyrosine Kinase Inhibitor | VEGFR-2, PDGFR-β | Solitary Fibrous Tumor (67) ASPS (68) |
| Lenvatinib | Tyrosine Kinase Inhibitor | VEGFR1-3; FGFR1-4; PDGFRα; c-kit; RET | Leiomyosarcoma (75) LPS (75) |
| Crizotinib | Tyrosine Kinase Inhibitor | c-Met; ALK; ROS1 | ASPS (76) |
| Palbociclib Abemaciclib |
CDK4/6 Inhibitor | CDK 4/6 | WD/DD LPS (78, 79) STS with high CDK4 expression (80) |
Platelet derived growth factor receptor (PDGFR); vascular endothelial growth factor receptor (VEGFR); stem cell growth factor receptor (c-kit); hepatocyte growth factor receptor (c-Met); anaplastic lymphoma kinase (ALK); cyclin dependent kinase (CDK); tenosynovial giant cell tumor (TGCT); Alveolar Soft Part Sarcoma (ASPS); well-differentiated/dedifferentiated liposarcoma (WD/DD LPS).